Regeneron Pharmaceuticals (REGN) Given a $483.00 Price Target by Leerink Swann Analysts
Leerink Swann set a $483.00 price target on Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Friday, The Fly reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. The analysts noted that the move was a valuation call.
Other equities analysts have also issued reports about the stock. ValuEngine raised shares of Regeneron Pharmaceuticals from a strong sell rating to a sell rating in a research report on Thursday, September 6th. BidaskClub raised shares of Regeneron Pharmaceuticals from a hold rating to a buy rating in a research report on Saturday, September 1st. Morgan Stanley increased their price objective on shares of Regeneron Pharmaceuticals from $409.00 to $412.00 and gave the company an equal weight rating in a research report on Thursday, October 11th. Cantor Fitzgerald increased their price objective on shares of Regeneron Pharmaceuticals to $441.00 and gave the company a neutral rating in a research report on Monday, October 22nd. Finally, JPMorgan Chase & Co. reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, October 2nd. Two investment analysts have rated the stock with a sell rating, seventeen have assigned a hold rating and five have given a buy rating to the company. Regeneron Pharmaceuticals currently has an average rating of Hold and an average price target of $406.89.
NASDAQ:REGN traded down $8.86 during mid-day trading on Friday, reaching $372.83. The company’s stock had a trading volume of 835,844 shares, compared to its average volume of 626,753. Regeneron Pharmaceuticals has a 1 year low of $281.89 and a 1 year high of $416.49. The firm has a market cap of $41.30 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 1.63 and a beta of 1.36. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.04 and a quick ratio of 3.30.
In related news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction that occurred on Monday, September 24th. The shares were sold at an average price of $388.65, for a total value of $777,300.00. Following the transaction, the director now owns 13,000 shares in the company, valued at approximately $5,052,450. The sale was disclosed in a filing with the SEC, which is available through this link. 12.42% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Cornerstone Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $296,000. Acadian Asset Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $513,000. Aperio Group LLC grew its stake in Regeneron Pharmaceuticals by 7.8% in the 2nd quarter. Aperio Group LLC now owns 28,332 shares of the biopharmaceutical company’s stock valued at $9,774,000 after acquiring an additional 2,045 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock valued at $1,085,000 after acquiring an additional 141 shares during the period. Finally, Commonwealth Equity Services LLC grew its stake in Regeneron Pharmaceuticals by 13.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 6,457 shares of the biopharmaceutical company’s stock valued at $2,228,000 after acquiring an additional 771 shares during the period. 67.24% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: What are catch-up contributions?
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.